Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer

British Journal of Cancer

Volumn 103, Issue 10, 2010, Pages 1479-1484

  Massoner, P ^a   Ladurner Rennau, M ^a   Eder, I E ^a   Klocker, H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

cancer therapy; IGF; insulin

Indexed keywords

ANTIDIABETIC AGENT; ERLOTINIB; HETERODIMER; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TARGETING; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA; LUNG NON SMALL CELL CANCER; MODULATION; NEOPLASM; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION;

AMINO ACIDS; DISEASE PROGRESSION; FATTY ACIDS; GLUCOSE; GLYCOGEN; HOMEOSTASIS; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; NEOPLASMS; RECEPTOR, IGF TYPE 2; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 78149465086     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605932     Document Type: Short Survey

References (40)

1. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30: 586-623
2. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905
3. Biedi C, Panetta D, Segat D, Cordera R, Maggi D (2003) Specificity of insulin-like growth factor I and insulin on Shc phosphorylation and Grb2 recruitment in caveolae. Endocrinology 144: 5497-5503
4. Broughton S, Partridge L (2009) Insulin/IGF-like signalling, the central nervous system and aging. Biochem J 418: 1-12
5. Chao W, D'Amore PA (2008) IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 19: 111-120
6. De Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13: 3611-3616
7. Dey BR, Spence SL, Nissley P, Furlanetto RW (1998) Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem 273: 24095-24101
8. Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23: 824-854
9. Ghosh P, Dahms NM, Kornfeld S (2003) Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4: 202-212
10. Gualberto A, Pollak M (2009) Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-3021
11. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
12. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y (2003) IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421: 182-187
13. Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingaert B, Mayne S, Fraumeni Jr J, Gammon MD (2009) IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. Int J Cancer 125: 2673-2678
14. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, Lee FY, Gottardis MM, Clark E, Helman L, Attar RM, Dongre A, Carboni JM (2009) The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69: 161-170
15. Hwa V, Oh Y, Rosenfeld RG (1999) The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20: 761-787
16. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, Moorehead RA (2007) Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 26: 1636-1644
17. Jui HY, Accili D, Taylor SI (1996) Characterization of a hybrid receptor formed by dimerization of the insulin receptor-related receptor (IRR) with the insulin receptor (IR): coexpression of cDNAs encoding human IRR and human IR in NIH-3T3 cells. Biochemistry 35: 14326-14330
18. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, Lewis MT, Gottardis MM, Wong TW, Attar RM, Carboni JM, Lee AV (2007) Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol 27: 3165-3175
19. LeRoith D, Roberts Jr CT (2003) The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137
20. Lewis DA, Travers JB, Somani AK, Spandau DF (2009) The IGF-1/IGF-1R signaling axis in the skin: a new role for the dermis in aging-associated skin cancer. Oncogene 29: 1475-1485
21. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66: 10100-10111
22. Nam T, Moralez A, Clemmons D (2002) Vitronectin binding to IGF binding protein-5 (IGFBP-5) alters IGFBP-5 modulation of IGF-I actions. Endocrinology 143: 30-36
23. Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J (2009) The role of liver-derived insulin-like growth factor-I. Endocr Rev 30: 494-535
24. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277: 39684-39695
25. Papa V, Russo P, Gliozzo B, Goldfine ID, Vigneri R, Pezzino V (1993) An intact and functional soluble form of the insulin receptor is secreted by cultured cells. Endocrinology 133: 1369-1376
26. Pezzino V, Papa V, Costantino A, Frittitta L, Russo P, Goldfine ID, Vigneri R (1992) Identification and initial characterization of insulin receptorlike immunoreactivity in human plasma. J Clin Endocrinol Metab 74: 1116-1121
27. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL (1997) Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 138: 1728-1735
28. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928
29. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353
30. Ross JA, Schmidt PT, Perentesis JP, Davies SM (1999) Genomic imprinting of H19 and insulin-like growth factor-2 in pediatric germ cell tumors. Cancer 85: 1389-1394
31. Sadowski T, Dietrich S, Koschinsky F, Sedlacek R (2003) Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. Mol Biol Cell 14: 4569-4580
32. Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806
33. Sasaoka T, Ishiki M, Sawa T, Ishihara H, Takata Y, Imamura T, Usui I, Olefsky JM, Kobayashi M (1996) Comparison of the insulin and insulinlike growth factor 1 mitogenic intracellular signaling pathways. Endocrinology 137: 4427-4434
34. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R (1993) Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90: 11217-11221
35. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M, Greenberg NM (2008) Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 68: 3495-3504
36. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D (2010) Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 107: 10791-10798
37. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363-374
38. Zhang B, Roth RA (1992) The insulin receptor-related receptor. Tissue expression, ligand binding specificity, and signaling capabilities. J Biol Chem 267: 18320-18328
39. 0-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 16: 1236-1244
40. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D (2004) PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23: 786-794